Back

Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3

28 August 2026 (16:30 - 16:45)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Luke Joseph Laffin

Cleveland Clinic, Cleveland (United States of America)

3 More presentations in this session

Presentation thumbnail
Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia
Professor D. Peng (Changsha, CN)
Slides Video
Presentation thumbnail
AAV8-mediated gene therapy for homozygous familial hypercholesterolemia
Doctor T. Li (Xi'an, CN)
Video
Presentation thumbnail
Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study
Doctor A. Sarraju (Cleveland, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 16:30 CET
You may be interested in
thumbnail
Congress Presentation
Can gene editing address unmet need in dyslipidaemia?
30 August 2025
thumbnail
Congress Presentation
SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study
1 September 2024
thumbnail
Congress Presentation
CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results
11 May 2026
thumbnail
Congress Session
Late-breaking science on pharmacology
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources